Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 23:4:25.
doi: 10.3389/fnmol.2011.00025. eCollection 2011.

Deoxyribozymes: new therapeutics to treat central nervous system disorders

Barbara Grimpe  1
Affiliations

Deoxyribozymes: new therapeutics to treat central nervous system disorders

Barbara Grimpe. Front Mol Neurosci. .

Abstract

This mini-review focuses on a knockdown technology called deoxyribozymes, which has rarely been utilized in the field of neurobiology/neuroscience. Deoxyribozymes are catalytic DNA molecules, which are also entitled DNA enzyme or DNAzyme. This mini-review presents a description of their development, structure, function, and therapeutic application. In addition, information on siRNA, ribozymes, and antisense are given. Further information on two deoxyribozymes against c-Jun and xylosyltransferase (XT) mRNA are summarized of which the first is important to influence many neurological disorders and the last potentially treats spinal cord injuries (SCIs). In particular, insults to the central nervous system (CNS) such as SCI generate an inhibitory environment (lesion scar) at the injury site that prevents the endogenous and therapy-induced axonal regeneration and thereby limits repair strategies. Presently, there are no treatments available. Hence, deoxyribozymes provide an opportunity for new therapeutics that alter the inhibitory nature of the lesion scar and thus promote axonal growth in the injured spinal cord. When used cautiously and within the limits of its ability the deoxyribozyme technology holds promise to become a major contributing factor in repair strategies of the CNS.

Keywords: DNA enzymes; brain insult; c-Jun; catalytic DNA; central nervous system trauma; drug development; proteoglycans; xylosyltransferase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure and digestion mechanism of deoxyribozymes. (A) Structure of the 10-23 and 8-17 deoxyribozyme. The catalytic loop digest the target mRNA (marked by the arrow) between an unpaired purine and a paired pyrimidine nucleotide. Binding to the mRNA occurs mostly via Watson–Crick base pairing. Note a G-T Hoogsteen base pair in the 8-17 deoxyribozyme (modified from Santoro and Joyce, 1997). (B) Transesterification of a target mRNA via a deoxyribozyme and divalent cations generates a 2′3′-cyclic phosphate and a 5′-hydroxyl termini as end product (modified from Achenbach et al., 2004).
See this image and copyright information in PMC

References

    1. Achenbach J. C., Chiuman W., Cruz R. P. G., Li Y. (2004). DNAzymes: from creation in vitro to application in vivo. Curr. Pharm. Biotechnol. 5, 321–336 10.2174/1389201043376751 - DOI - PubMed
    1. Adams M., Cavanagh J. F. (2004). International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP): another step forward for spinal cord injury research. Spinal Cord 42, 273–280 10.1038/sj.sc.3101597 - DOI - PubMed
    1. Antoniou X., Falconi M., DiMarino D., Borsello T. (2011). JNK3 as a therapeutic target for neurodegenerative diseases. J. Alzheimers Dis. 24, 633–642 - PubMed
    1. Armstrong B. C., Krystal G. W. (1992). Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc. Cell Growth Differ. 3, 385–390 - PubMed
    1. Baccarini P., Fiorentino M., D’Errico A., Mancini A. M., Grigioni W. F. (1993). Detection of anti-sense transcripts of the insulin-like growth factor-2 gene in Wilms’ tumor. Am. J. Pathol. 143, 1535–1542 - PMC - PubMed